India Pharma Outlook’s June Edition - 2026: The edition has been prepared after being closely scrutinized by a distinguished panel of judges including CXOs, analysts, and our editorial board. We recognize their valuable contribution to the ever expanding and competitive market and their ability to sustain themselves and emerge as top contestants through their reliable products.
“Bliss Lifesciences has built its innovation strategy around anticipating these global demand shifts before they become mainstream in emerging markets” - Bliss Lifesciences
“With a strong emphasis on quality systems, research-driven development, and customer-centric innovation, Esvee continues to strengthen its presence in an increasingly competitive and technology-driven market” - Esvee Biologicals
“Holy Evolution Pharma has strategically built its portfolio around specialized neuro and psychiatric formulations aimed at improving treatment accessibility and patient well-being” - Holy Evolution Pharma
“J & D Pharmaceuticals emphasizes rigorous adherence to Good Clinical Practice (GCP) standards across its operations. The company’s internal culture prioritizes academic integrity, scientific discipline, and clinical accountability” - J & D Pharmaceuticals
“S V Chem Intermediates has built its operations around GMP-compliant manufacturing systems supported by ISO-certified...
.jpg "June Special")
Our subscribers play a decisive role in finalization of our annual list of June Edition - 2026 by nominating those which have served them with excellence and are praiseworthy. If you feel there is a company that deserves to be on our annual list, do write to us about them mentioning their value proposition.
 |  | Bliss Lifesciences | The global nutraceutical industry is entering a decisive phase of transformation. Rising preventive healthcare awareness, personalized nutrition trends |
 |  | Esvee Biologicals | The global life sciences industry is undergoing a significant transformation, driven by rising pharmaceutical production, stringent quality regulations |
 |  | Holy Evolution Pharma | As demand rises for affordable and specialized medicines in Tier II and Tier III cities, pharmaceutical companies are increasingly focusing on stronger distribution ecosystems, dependable supply chains, and partner-led growth models. |
 |  | J & D Pharmaceuticals | Recent industry estimates project the global anti-inflammatory therapeutics market to exceed USD 130 billion over the next decade |
 |  | S V Chem Intermediates | The pharmaceutical industry is witnessing a major shift toward peptide-based therapeutics, creating strong demand for protected amino acids and spe¬cialty pharmaceutical intermediates. |
